Stories from people navigating ESR1 mutation — diagnosis, treatment, caregiving, and the ordinary days in between.
7 stories
Women's Health
The FDA indication ties imlunestrant plus abemaciclib to an ESR1-positive result after endocrine therapy progression in ER-positive, HER2-negative advanced breast cancer.
Rayan Salih · November 5, 2026 · 6 min
Women's Health
The FDA approval applies to adults with ER-positive, HER2-negative advanced or metastatic breast cancer harboring an ESR1 mutation after endocrine-therapy progression. Guardant360 CDx is the companion diagnostic.
Rayan Salih · 7 min read
Women's Health
The FDA-approved imlunestrant–abemaciclib combination applies to adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine progression.
Rayan Salih · 7 min read
Women's Health
FDA approval makes an emerging ESR1 mutation actionable during aromatase-inhibitor plus CDK4/6-inhibitor therapy for eligible patients with advanced breast cancer.
Rayan Salih · 6 min read
Oncology
The FDA approved imlunestrant plus abemaciclib for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy progression.
Rayan Salih · 6 min read
Women's Health
The FDA approved imlunestrant plus abemaciclib for adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer that progressed after endocrine therapy.
Rayan Salih · 6 min read
Oncology
FDA approval makes vepdegestrant an option for adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after prior endocrine therapy.
Dr. Abu Bakar · 6 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.